Claims
- 1. A conjugate which consists essentially of a compound of formula I: ##STR7## wherein --CH.sub.2 R.sub.1 is --CH.sub.2 OR.sub.2 where R.sub.2 is a primary or secondary alkyl containing 1 to 20 carbons: and
- R.sub.3 is --CH.sub.2 CH.sub.2 COR.sub.4 where R.sub.4 is H or an alkyl group containing from 1 to 20 carbon atoms,
- covalently bound to a target-specific component.
- 2. The conjugate of claim 1 wherein the component is an immunoglobulin or a receptor ligand.
- 3. A pharmaceutical composition useful for labeling malignant tissue which comprises the conjugate of claim 1 associated with a label in admixture with a pharmaceutically acceptable excipient.
- 4. A conjugate which consists essentially of a target-specific component covalently bound to a compound of formula II: ##STR8## wherein R.sub.5 is --OR.sub.6 where R.sub.6 is a primary or secondary alkyl containing 6 to 20 carbons; and
- R.sub.7 is --CH.sub.2 CH.sub.2 CO.sub.2 R.sub.8 where R.sub.8 is H or an alkyl containing 1 to 20 carbons.
- 5. The conjugate of claim 4 wherein the component is an immunoglobulin or a receptor ligand.
- 6. A pharmaceutical composition useful for labeling malignant tissue which comprises the conjugate of claim 4 associated with a label in admixture with a pharmaceutically acceptable excipient.
- 7. A method of treating a human with abnormal cells which replicate at an abnormally high rate, comprising the steps of:
- administering to the human a therapeutically effective amount of a compound of formula II ##STR9## wherein R.sub.5 is --OR.sub.6 where R.sub.6 is a primary or secondary alkyl containing 6 to 20 carbons; and
- R.sub.7 is --CH.sub.2 CH.sub.2 CO.sub.2 R.sub.8 where R.sub.8 is H or --CH.sub.3 ;
- allowing the compound of formula II to accumulate on the abnormal cells; and
- irradiating the compound of formula I with light having a wavelength of about 660 nm, which is absorbed by the compound of formula I, thereby generating a cytotoxic effect with respect to the abnormal cells.
CROSS-REFERENCES
This application is a continuation of our earlier filed application Ser. No. 07/973,174 filed Nov. 9, 1992, now issued as U.S. Pat. No. No. 5,314,905; which is a divisional of Ser. No. 07/822,409 filed Jan. 17, 1992, now issued as U.S. Pat. No. 5,198,460; which is a continuation-in-part of Ser. No. 07/597,786 filed Oct. 15, 1990, now issued as U.S. Pat. No. 5,093,349; which is a continuation of Ser. No. 07/221,804 filed Jul. 20, 1988, now issued as U.S. Pat. No. 5,002,962; all of which are incorporated herein by reference and to which we claim priority under 35 U.S.C. .sctn.120.
US Referenced Citations (8)
Non-Patent Literature Citations (6)
Entry |
Lipson et al., The Use of a Derivative of Hematoporphyrin in Tumor Detection, 26 J. Natl. Cancer Institute 1-8 (1961). |
Dougherty et al., Photoradiation Therapy--Clinical and Drug Advances, 160 Adv. Exp. Med. Biol. 3-13 (1983). |
Kessel et al., Chemistry of Hematoporphyrin-derived Photosensitizers, 46 Photochem. and Photobiol. 563-68 (1987). |
Scourides et al., Nature of the Tumor-localizing Components of Hematoporphyrin Derivatives, 47 Cancer Research 3439-45 (1987). |
Pandey et al., Synthesis and Photosensitizing Activity of a Di-porphyrin Ether, 109 Chem. Abstracts 320, Abstract No. 125066b (1988). |
Juergens et al, Chemical Abstracts, vol. 92 (1979) 110984. |
Divisions (1)
|
Number |
Date |
Country |
Parent |
822409 |
Jan 1992 |
|
Continuations (2)
|
Number |
Date |
Country |
Parent |
973174 |
Nov 1992 |
|
Parent |
221804 |
Jul 1988 |
|
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
597786 |
Oct 1990 |
|